Quintiles and IMS Health announced a global strategic alliance to generate real-world evidence (RWE) and apply insights to drive late-stage clinical research. The collaboration combines IMS Health’s access to 500+ million anonymous patient records, as well as its scalable Evidence 360 RWE platform. Quintiles is providing experience in real-world and late-phase programs involving more than 74,000 sites and more than 650,000 enrolled patients in more than 100 countries since 2011 along with its award-winning Quintiles Infosario® platform. This combination will enable biopharmaceutical companies to optimize physician and patient recruitment, streamline data collection and study execution, as well as improve the quality and impact of real-world evidence worldwide.
Read the full release.